Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus MDI as add-on therapy to ICS + LABA in moderate to severe asthma
2004-002078-45Phase 2Completed
- Sponsor
- Fujisawa Pharmaceutical
- Start
- Sep 2004
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tacrolimus in asthma (3 arms), sponsored by Fujisawa Pharmaceutical. Primary endpoint: Change in maximum FEV1 from baseline to day 84. Started Sep 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
asthma
Beyond the preview
Go deeper on 2004-002078-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002078-45.